New data shows ReNeuron’s lead CTX cell therapy candidate can be re-programmed into a pluripotent state and differentiated into other cell types

18 October 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 26th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Lausanne, Switzerland.

Read more…

Back